Effect of a pharmacotherapeutic follow-up program in patients with systemic arterial hypertension

• Autor(a) principal: Marques, Lais Alves
• Data de Publicação: 2021
• Outros Autores: Souza, Cristina da Silva, Viana, Lorrany Mayandra Leite Souto, Oliveira, Izabel Luiza Batista, Santos, Yane Silva, Araújo, Tiago Ferreira da Silva, Silva, Daniel Tenório da
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Saúde e Pesquisa (Online)
• Texto Completo: https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/9133
• topic: Outcome and process assessment (Health Care); Pharmaceutical services; Systemic arterial hypertension; Avaliação de processos e resultados (Cuidados de Saúde); Cuidados farmacêuticos; Hipertensão arterial sistêmica; Hipertensão; acompanhamento farmacoterapêutico

Systemic Arterial Hypertension (SAH) is a multifactorial clinical condition with non-pharmacological and/or pharmacological treatment that requires pharmacotherapeutic monitoring in order to manage the health condition. The objective was to evaluate the impact of a pharmacotherapeutic follow-up program of patients with SAH through a quasi-experimental, longitudinal, and prospective study. Twenty-eight patients were evaluated, 50% of which had decompensated blood pressure; the DRPs identified were drug interactions (57.1%), pharmacotherapeutic duplication (28.8%), potentially inappropriate medication use in older adults (38.5%), and non-adherence to treatment (89.3%). Of the NOM identified (Negative Outcomes associated with Medication), 56.2% were related to safety, and 37.5% to effectiveness. After the follow-up, 56.3% of the NOM were resolved, 57.1% of patients adhered to treatment, and there was a reduction in the Systolic Blood Pressure (p = 0.010) and Diastolic Blood Pressure (p = 0.020). The program proved to be efficient in reducing systemic blood pressure and resolving DRPs and NOM.